CSL Behring Therapies

CSL Behring offers a wide range of plasma-derived and recombinant therapies and pharmaceuticals for the treatment of bleeding disorders.

For hemophilia A, CSL Behring offers Helixate^® FS. Helixate^® FS is indicated for the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor VIII (FVIII). Learn more

If your child is currently using another factor VIII (FVIII) product for hemophilia A, consider the benefits of Helixate^® FS. When you participate in the Sample Program, you will receive up to 6,000 IU of Helixate^® FS!

How Do I Get My Sample?

Print out the Sample Program Product Request form and take it to your doctor. Talk to your doctor to see if Helixate^® FS is right for your child and to discuss how to switch. Then have your doctor fill out the request form and fax it to us at the number shown on the bottom of the form. The sample will be delivered to your doctor for you to pick up.

For hemophilia B, CSL Behring offers Mononine^® (Coagulation Factor IX [Human] Monoclonal Antibody Purified. Mononine^® is indicated for the prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease. Learn more

For information on all CSL Behring products, explore our US products site.

Mix2Vial™ is a trademark of Medimop Medical Projects Ltd.

CSL Behring

CSL Behring

Important Safety Information | Prescribing Information | Contact Us | Site Map
Privacy Statement | Terms of Use | About CSL Behring | Helixatefs.com

© CSL Behring 2010. The product information presented on this site is intended for US residents only.

Important Safety Information for Helixate^®FS

Helixate^® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Important Safety Information for Mononine^®

Mononine^® is contraindicated in patients with known hypersensitivity to mouse protein.

The following adverse reactions may be observed after administration: headache, fever, chills, flushing, nausea, vomiting, tingling, lethargy, hives, stinging or burning at the infusion site, or other manifestations of allergic reactions, including anaphylaxis.

Mononine^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

For more information about Mononine^®, please see the full Prescribing Information.